Abstract: A pharmaceutical composition for treating an ischemic tissue, comprising: a core component and a matrix component, wherein the core component includes a heparin or derivative thereof and the matrix component includes a hyaluronan or derivative thereof, the pharmaceutical composition having a viscosity greater than 10 mPa-s.

Abstract: A composition comprised of a plurality of levan oligomers, wherein at least 70% (w/w) of said plurality of levan oligomers are characterized by: (i) weight average molecular weights (MW) of 540 to 1000 g/mole, and (ii) a dispersity index (Ð) of less than 2 is disclosed herein. Uses of the levan composition, such as, as a feed additive, growth promoter and for improving the rejuvenation and healing of a human skin, are also disclosed.

Abstract: A hydrocolloid or aqueous solution comprising a poly alpha-1,3-glucan ether compound is disclosed having a viscosity of at least about 10 centipoise (cPs). The poly alpha-1,3-glucan ether compound in these compositions has a degree of substitution of about 0.05 to about 3.0. Also disclosed is a method for increasing the viscosity of a hydrocolloid or aqueous composition using a poly alpha-1,3-glucan ether compound.

Abstract: Wound-care composition and method of use. The composition comprises: a substrate; potassium alum; and urea. The potassium alum makes up 10.27 wt. % of the composition within a tolerance of +/- 50%; and the urea makes up 0.12 wt. % of the composition within a tolerance of +/- 50%. The method comprises applying the composition to a wound on a non-human animal.

Abstract: A method of preparing a hydrogel product including crosslinked glycosaminoglycan molecules, said method including: i) providing a glycosaminoglycan crosslinked by amide bonds, wherein the crosslinked glycosaminoglycans include residual amine groups; and ii) acylating residual amine groups of the crosslinked glycosaminoglycans provided in i) to form acylated crosslinked glycosaminoglycans.

Abstract: Herbal composition having an effect of reducing uric acid, which is made from the following herbal materials in specified portions by weight: 4-30 portions of Glabrous greenbrier rhizome, 2-15 portions of Chicory, 2-15 portions of Herba Plantaginis, 2-20 portions of Coix seed, and 2-10 portions of Kudzuvine Root. The composition may be used in combination with modern Western medicines to achieve optimal effects.

Abstract: The present disclosure generally relates to a fish feed or fish feed product including a binding agent that increases the particle size and stability of feces produced by fish that consume the fish feed or fish feed product. In general, the fish feed will include a binding against such as locust bean gum, cassia gum, xanthan gum, tara gum, or combinations thereof. Also provided are methods for increases fish feces stability and methods for eliminating suspended solids from a recirculating aquaculture system.

Abstract: The present invention relates to a method for producing fucosylated oligosaccharides by using a recombinant prokaryotic host cell that is cultivated on a gluconeogenic substrate, as well as to the host cell and its use. The host cell is genetically modified in that the activity of a fructose-6-phosphate converting enzyme is abolished or lowered, and the transport of the produced fucosylated oligosaccharide through the cell membrane is facilitated by an exogenous transport protein.

Abstract: The present invention relates to delivery devices adapted to mechanically dilate a pelvic anatomical canal, the delivery devices comprise a composition formulated as a gel comprising a beneficial or therapeutic agent, said delivery devices being capable of releasing the beneficial or therapeutic agent into the pelvic anatomical canal, specifically into the vaginal canal, and thereby treat vaginal conditions associated with vaginal narrowing, atrophy, or dryness.

Abstract: Systems, devices, methods, and kits for monitoring one or more physiologic and/or physical signals from a subject are disclosed. A system including a head mounted display to monitor one or more physiologic signals from the face or head of the subject is disclosed. A method for analyzing an ocular parameter of the subject to determine a sympathetic and a parasympathetic outflow thereto is disclosed.

Abstract: Provided are pharmaceutical compositions comprising an anion exchanger and a calcium salt; methods for inducing hemostasis at a site of bleeding by applying to the site of bleeding an effective amount of the compositions; and methods of preparation of the compositions.

Abstract: Antimicrobial polymer coating formulations are prepared that protect biological surfaces by treating, reducing, ameliorating, preventing or inhibiting pathogenic microorganism ingress to a human or animal host, reducing the potential for infection, particularly by necrotizing fasciitis originating microorganisms, through use of a polymer coating barrier containing antimicrobial agents that facilitates sustained release of biocidal agents active against such opportunistic microorganisms. Such formulations are effective for inhibiting microbial ingress pertaining to soft tissue and skin tears, abrasions, punctures and surgical wounds, and can be used as in water environments and as a skin protectant sunscreen and insect repellent.

Abstract: A cosmetic or dermocosmetic agent consisting of: galactomannans having molecular weights between 5 and 630 kDa, and crosslinked sulfated galactans having molecular weights between 7 and 3000 kDa. Methods of using the agent, including for skin tensing and rejuvenation.

Abstract: This disclosure provides, in one aspect, dosing strategies for soluble ?-glucan immunotherapy to optimize acute immunopharmacodynamic responses for the immunotherapy and/or subject. It also provides a method for analyzing a sample from a subject for a biomarker to identify the appropriate dosing strategy for soluble ?-glucan immunotherapy. Generally, the method includes obtaining a biological sample from a subject, analyzing the sample for a biomarker anti-?-glucan antibody level or immunopharmacodynamic response level, classifying the subject into a subgroup based on the biomarker anti-?-glucan antibody level or immunopharmacodynamic response level and identifying the appropriate dosing strategy based on the subgroup classification.

Abstract: SAE-CD compositions are provided, along with methods of making and using the same. The SAE-CD compositions comprise a sulfoalkyl ether cyclodextrin having an absorption of less than 0.5 A.U. due to a drug-degrading agent, as determined by UV/vis spectrophotometry at a wavelength of 245 nm to 270 nm for an aqueous solution containing 300 mg of the SAE-CD composition per mL of solution in a cell having a 1 cm path length.

Abstract: The invention disclosed herein relates to a composition and method of reducing the joint pain associated with hemarthrosis or hemophilic arthropathy. The method includes administering a COX-2 inhibitor, such as rofecoxib, celecoxib, valdecoxib, etoricoxib or other “coxib” drug which is encapsulated in PLGA micro-particles. The COX-2 inhibitor can be administered directly to an area where pain exists by an injection device. In a preferred embodiment, rofecoxib or celecoxib can be encapsulated in PLGA micro-particles for controlled, sustained release over a 2-8-week period. The non-systemic delivery and the controlled, sustained release of rofecoxib alleviate the cardiovascular side effects associated with systemic rofecoxib treatments.

Abstract: Provided herein are methods of treating ST-elevation myocardial infarction (STEMI) and diseases of the digestion system using ?-1,3/1,6-D-glucan derived from mycellium extract of Ganoderma lucidum. Methods of treating ST-elevation myocardial infarction (STEMI) and diseases of the digestion system using a polysaccharide comprising ?-1,3/1,6-D-glucan are also provided.

Abstract: A preparation of a homogeneous polysaccharide from a Radix Puerariae aqueous extract is provided and the lipid-lowering activity of the polysaccharide is studied. It is proved through in vivo experiments that the homogeneous polysaccharide QL extracted from Radix Puerariae (a genuine medicinal material in Jiangxi Province) in the present disclosure has significant lipid-lowering activity, can significantly reduce a serum triglyceride content and a liver index, and can be used to develop a potential safe and effective lipid-lowering drug.

Abstract: The present application relates to beta-1,3-glucan and uses thereof to modulate immunity in the human body. Also provided are methods for treatment and/or prevention of high cholesterol, diabetes, and allergies. Also provided are methods for treatment and/or prevention of intestinal inflammation.

Abstract: This invention provides a high molecular weight polysaccharide capable of binding to and inhibiting virus and related pharmaceutical formulations and methods of inhibiting viral infectivity and/or pathogenicity, as well as immunogenic compositions. The invention further includes methods of inhibiting the growth of cancer cells and of ameliorating a symptom of aging. Additionally, the invention provides methods of detecting and/or quantifying and/or isolating viruses.

Abstract: A crosslinked polymeric network is disclosed. The crosslinked polymeric network comprises a reaction product of a first glycosaminoglycan, a second glycosaminoglycan, and a crosslinking agent, wherein the first glycosaminoglycan is different than the second glycosaminoglycan.

Abstract: A composition for the prevention and treatment of the oral cavity comprising hyaluronic acid and a Manuka-derived product is described. The composition of the invention stabilizes the hyaluronic acid protecting the same from the aggression of the hyaluronidase present in the oral cavity, in particular on the mucous membranes and on the gingival walls, thus increasing the overall efficacy and the therapeutic effect.

Abstract: Disclosed is a method for filling a root canal in a tooth. The method includes positioning a fiber in the root canal of the tooth, filling at least a portion of the root canal with an unset hydrogel composition, such that the unset hydrogel composition contacts at least a portion of the fiber, setting the hydrogel composition, thereby forming a set hydrogel, and removing the fiber from the set hydrogel, thereby leaving a channel in the set hydrogel. Methods and kits for repairing teeth are also described.

Abstract: The composition is a hydrogel which may be used to deliver therapeutics vaginally. The hydrogel may include a glycosaminoglycan. The glycosaminoglycan may include multiple thiol groups. The composition may also include a molecule that includes at least two thiol reactive sites. The composition may include a mucoadhesive agent as well as a therapeutic agent. The composition may deliver the therapeutic at a pH that is optimal for the vaginal environment, namely between about 3.5 and 5.0.

Abstract: A synthetic composition for use in improving one or more co-morbid mental disorder symptoms of a patient with IBS, characterised in that the composition contains an effective amount of one or more neutral human milk oligosaccharides, is disclosed.

Abstract: The invention comprises a method of industrial extraction of alginates from brown seaweeds of the family Sargassaceae of the order Fucales, as well as the product resulting from the method. The method includes the following stages: preparation of raw materials, crushing of the algae, pressure boiling of the algae, mixing the boiled algae with water, purification of the diluted algal mass, extraction of alginic acid, washing of the alginic acid, dehydration of the alginic acid, treatment of the alginic acid with sodium hydrogen carbonate, clarification of resultant sodium alginate solution, precipitation of sodium alginate gel, and drying of the sodium alginate gel.

Abstract: The invention provides a pharmaceutical composition of hyaluronic acid comprising repeating units of a disaccharide comprising glucuronic acid and N-acetylglucosamine, wherein a portion of the N-acetyl groups of the N-acetylglucosamine have been independently replaced with a group of the formula —N—C(O)—(C2-C4)-alkyl for treating hyperuicemia and gouty arthritis. Studies show that this composition is promising as an anti-gout therapeutic agent, which combines both anti-inflammatory actions as well as anti uracemic effects.

Abstract: Provided are a composition for inhibiting immune cell proliferation, including sialyllactose or a derivative thereof as an active ingredient, and a method of inhibiting immune cell proliferation, wherein the composition and the method may decrease expression of chemokines, decrease expression of pro-inflammatory cytokines, decrease production of inflammatory mediators, decrease expression of COX2, and decrease production of PEG2, and therefore, may be useful for the prevention or treatment of atopic dermatitis or arthritis.

Abstract: Described herein are methods for preventing a serious health consequence and/or tissue damage in a subject after the subject has been exposed to ionizing radiation and/or chemotherapy. The methods involve administering to the subject a sulfated polysaccharide or the pharmaceutically acceptable salt or ester thereof after the subject has been exposed to ionizing radiation and/or chemotherapy. The methods described herein are most beneficial to cancer patients who suffer from mucositis after exposure to ionizing radiation.

Abstract: A method for manufacturing a hyaluronan conjugate comprises providing hyaluronan in solation or gel form, reacting the hyaluronan in solution or gel form with anhydride reagent to provide a hyaluronan hemi-ester with a chain of length L between the hyaluronan and the ester group, and subsequently binding the hyaluronan hemi-ester to a pharmaceutically active compound. A hyaluronan conjugate comprises hyaluronan having free hemi-ester-groups and a pharmaceutically active compound bound to the hyaluronan via hemi-ester groups, wherein the hemi-ester groups have a chain length of 2-9 atoms. The hyaluronan conjugate is suitable for use in various methods of treatment in human or veterinary medicine and for preparation of a medicament for use in human or veterinary medicine.

Abstract: The present invention relates to a method for producing a flavour composition comprising providing a slurry of yeast cell walls and contacting the slurry of yeast cell walls with a glucanase and with an endoprotease, followed by separating a liquid fraction by solid/liquid separation to provide the liquid flavour composition.

Abstract: The present invention relates to the medical use of polysulfated polysaccharides and compositions thereof for the treatment of disease or disorders associated with bone marrow pathologies in the musculoskeletal system of a mammal. In particular, the invention relates to use of polysulfated polysaccharides, such as pentosan polysulfate, in treatment of bone marrow edema lesions or spinal Modic Endplate Changes as assessed by magnetic resonance imaging (MRI).

Abstract: The present invention provides frozen confectionery (sherbet and frozen confectionery containing ice) containing a specific amount of isomaltodextrin that is easy to loosen without affecting a flavor.

Abstract: The invention relates to a cosmetic active ingredient comprising at least one Metschnikowia reukaufii extract, and the use of same for the cosmetic treatment of the skin, in particular for improving the radiance of the complexion by acting on the skin microbiota. The active ingredient is effective on mature skin. The invention also concerns compositions comprising the cosmetic active ingredient and a cosmetic method for treating the skin using these compositions.

Abstract: Disclosed are nutraceutical formulations, and methods of using these nutraceutical formulations for the mitigation of chronic malnutrition in an infant, wherein the infant is breast feeding from a lactating mother ingesting one or more of said nutraceutical formulations in accordance with a prescribed regimen.

Abstract: The invention relates to human milk oligosaccharides (HMO) and its use in treatment of autism spectrum disorder (ASD).

Abstract: A method and a composition comprising human milk oligosaccharides for decreasing the production of detrimental proteolytic metabolites such as ammonia and branched chain fatty acids in the intestinal microbiota of humans, which is useful for the treatment of brain-gut disorders like autism, stress, anxiety, and depressive disorders, are disclosed. Methods of treatment of colon cancer and liver damage are also disclosed.

Abstract: The present disclosure provides soluble dietary fibers, food and beverage products including them, and methods for using them. In one aspect, the disclosure provides soluble dietary fiber having a fiber content of at least 97% as measured by AOAC 2001.03 and a DP1+DP2 content of no more than 3 wt % (e.g., no more than 2 wt %) on a dry solids basis. The soluble dietary fiber can be useful in variety of food and beverage applications including fermented foods and beverages like beer and sake.

Abstract: Disclosed are nutraceutical formulations, including extracts comprising the hydrophilic and lipophilic fractions of stabilized rice bran. Also disclosed are methods for using said nutraceutical formulations for the management or remediation of conditions related to type II diabetes in humans, including methods for decreasing HbA1c and fasting glucose blood concentrations, and for increasing serum fasting insulin levels.

Abstract: Compositions comprising oxidized dextran compounds are disclosed herein. Oxidized dextran compounds are produced by contacting dextran under aqueous conditions with at least one N-oxoammonium salt, at least one periodate compound, and/or at least one peroxide compound.

Abstract: The invention relates to a composition for use in the prevention or treatment of Salmonellosis in animals, said use comprising administering the composition to the animal, wherein the composition contains at least 0.01% by weight of dry matter of rhamnogalacturonan I (RG-I) polysaccharides having a molecular weight of more than 2 kDa and having a backbone consisting of galacturonic acid residues and rhamnose residues, said rhamnose residues being contained in alpha(1?4)-galacturonic-alpha(1?2)-rhamnose residues, wherein the molar ratio of galacturonic acid residues to rhamnose residues in the RG-I polysaccharides is within the range of 50:1 to 1:1. The use of RG-I polysaccharides in the treatment or prevention of Salmonellosis provides an alternative for the widespread use of antibiotics. Furthermore, these RG-I polysaccharides may be used to prevent or treat Salmonellosis caused by Salmonella strains with resistance to antibiotics.

Abstract: A food supplement comprising a therapeutically effective amount of a composition is described. The composition includes hydrolyzed collagen, hyaluronic acid, ascorbic acid, and glucosamine hydrochloride. The composition may also include a cannabinoid or prodrug, vitamin C, vitamin D, and/or vitamin E. The therapeutically effective amount of the composition is effective in alleviating at least one symptom of a degenerative joint disease in a human or may be used for the prophylaxis of the degenerative joint disease in the human. The at least one symptom of the degenerative joint disease in the human includes joint pain and mobility pain.

Abstract: A compound that includes a dextran backbone having at least one C-type lectin targeting moieties attached thereto. Also disclosed are embodiments of the compound that include at least one therapeutic agent and/or at least one detection label attached to the dextran backbone. The compound may be effective for treatment of Corona Covid-19 (SARS-covid-2) virus, its variants and other related viral diseases, and disorders. Further disclosed are methods for diagnosing and treating diseases and/or disorders directly using the disclosed compounds.

Abstract: Use of a sophorolipid in the preparation of a feed supplement for the improvement of feed efficiency in an animal. A feed supplement comprising a sophorolipid and lysolecithin mix is also provided for improving the feed conversion rate of an animal.

Abstract: Some embodiments of the invention include methods for treating an animal for disease or nerve damage, comprising administration of a composition comprising a myelination enhancing inhibitor to the animal. Other embodiments of the invention include methods for treating an animal for disease or nerve damage, comprising administration of a composition comprising an HDAC3 inhibitor to the animal. Still other embodiments of the invention include methods for treating an animal for MS or nerve damage, comprising administration of a composition comprising an HDAC3 inhibitor to the animal. Additional embodiments of the invention are also discussed herein.

Abstract: The polysaccharide released from the unicellular cyanobacterium Cyanothece sp. CCY 0110 exhibits low cytotoxicity and proves to be suitable for the delivery of macromolecules. The cyanobacterium extracellular polymer disclosed in the present subject-matter, namely a polysaccharide and more in particular an heteropolysaccharide, assembles with proteins into a new phase with gel-like behaviour and the release kinetics can be modulated (i.e., delayed) by adding divalent cations and/or also exhibits physical and chemical properties typical of a bioemulsifier or a bioflocculant.

Abstract: Provided herein are compositions comprising a biocompatible microsphere, a biofilm-generating probiotic bacterium, a prebiotic, and/or a prebiofilmic. Methods for preparing and formulating the compositions and methods for treating or preventing a disease using the compositions are also provided.

Abstract: The invention relates to a human milk oligosaccharide (HMO) for use in, a synthetic composition comprising an HMO for use in, and a method for the treatment of, secondary prevention of, and/or induction of tolerance to non-coeliac wheat and/or gluten sensitivity in a human.

Abstract: A highly-sulfated modified fucan comprising a therapeutically effective, medically acceptable fucan in a composition comprising a sulfate to fucose molar ratio of greater than or equal to about 1.2, 1.81 or 1.9 and/or a sulfate to fucose plus galactose molar ratio of greater than or equal to about 1.1, 1.2 or 1.3.

Abstract: The topical cosmetic compositions and methods of the subject invention can be used to treat and/or prevent a variety of skin conditions, including, for example, age spots, acne, scars, body odor, aging-related conditions (e.g., wrinkles, looseness and dryness), and scalp issues (e.g., dandruff, seborrheic dermatitis and hair loss). In preferred embodiments, the compositions according to the subject invention comprise biological amphiphilic molecules produced by microorganisms.